Brought to you by 
Theravance completes $91.5mm IPO
Jun 2004
Executive Summary
Theravance (developing small-molecule therapeutics) has completed its initial public offering. The company sold 6.15mm common shares priced at $16 each, netting $91.5mm, just shy of the $96mm it had hoped to bring in.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Theravance completes $91.5mm IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice